Rossi Marco, DeCarolis Giuliano, Liberatoscioli Goffredo, Iemma Domenico, Nosella Paola, Nardi Luigi F
UCSC Faculty of Medicine, Dept. of Anesthesia and Intensive Care Policlinico A. Gemelli, Rome, Italy.
Azienda Ospedaliera Universitaria, Pisana, Pisa, Italy.
Pain Physician. 2016 Jan;19(1):E121-8.
BACKGROUND: Peripheral neuromodulation is often used as chronic neuropathic pain treatment. Percutaneous electrical nerve stimulation (PENS) is generally utilized with several probes at the same time and repeated treatments. OBJECTIVES: Evaluate the short- and long-term efficacy of a single probe and single shot PENS approach. STUDY DESIGN: Multicenter, prospective, observational study. SETTING: Four Italian pain therapy centers. METHODS: Inclusion criteria were age = 18 and = 80 years, presence of severe peripheral neuropathic pain lasting more than 3 months, localized and refractory to pharmacological therapies. Patients with infection, coagulopathies, psychiatric disorders, pacemakers, or implantable cardiac defibrillators were excluded. PATIENTS: Seventy-six patients (47 women, 29 men), mean age 62 ± 14 years, affected by neuralgia (21 herpes zoster infection, 31 causalgia, 24 postoperative pain) were enrolled in the study. INTERVENTION: After localization of trigger point and/or allodynic/hyperalgesic area, PENS therapy was achieved with a single 21 gauge conductive probe tunneled percutaneously and a neurostimulator device. MEASUREMENT: Numerical Rating Scale (NRS) and Neuropathic Pain Scale (NPS) were assessed at baseline, 60 minutes after PENS, at one week, after one, 3, and 6 months; perceived health outcome was measured with Euroqol-5 dimension (EQ-5D) questionnaire at baseline and at 6 months. Adverse events and patient satisfaction were reported. RESULTS: NRS and NPS decreased significantly after 60 minutes and the reduction remained constant over time at follow-up. EQ-5D increased significantly with respect to the baseline. Two nonclinically significant adverse events (one contralateral dysestesia and one self-resolving hematoma) were observed. LIMITATIONS: Small sample size and non-randomized observational study; high prevalence of post-herpetic and occipital neuralgias. CONCLUSION: PENS therapy produced significant and long-lasting pain relief in chronic peripheral neuropathic pains of different etiology. The present study confirms the feasibility, safety, and repeatability of this minimally invasive technique.
背景:周围神经调节常用于慢性神经性疼痛的治疗。经皮电神经刺激(PENS)通常同时使用多个探头并进行重复治疗。
目的:评估单探头单次PENS治疗方法的短期和长期疗效。
研究设计:多中心、前瞻性、观察性研究。
研究地点:四个意大利疼痛治疗中心。
方法:纳入标准为年龄在18至80岁之间,存在持续超过3个月的严重周围神经性疼痛,疼痛局限且对药物治疗无效。排除有感染、凝血功能障碍、精神疾病、起搏器或植入式心脏除颤器的患者。
患者:76例患者(47名女性,29名男性),平均年龄62±14岁,患有神经痛(21例带状疱疹感染、31例灼痛、24例术后疼痛)被纳入研究。
干预:在确定触发点和/或痛觉过敏/痛觉超敏区域后,使用一根21号经皮穿刺的导电探头和神经刺激器设备进行PENS治疗。
测量:在基线、PENS治疗后60分钟、1周、1个月、3个月和6个月时评估数字疼痛评分量表(NRS)和神经病理性疼痛量表(NPS);在基线和6个月时使用欧洲五维健康量表(EQ-5D)问卷测量感知健康结果。报告不良事件和患者满意度。
结果:60分钟后NRS和NPS显著降低,随访期间降低幅度保持稳定。EQ-5D相对于基线显著增加。观察到两例无临床意义的不良事件(一例对侧感觉异常和一例自行消退的血肿)。
局限性:样本量小且为非随机观察性研究;带状疱疹后神经痛和枕神经痛的患病率高。
结论:PENS治疗在不同病因的慢性周围神经性疼痛中产生了显著且持久的疼痛缓解。本研究证实了这种微创技术的可行性、安全性和可重复性。
Pain Physician. 2016-1
Lancet. 2021-5-29
Neuromodulation. 2019-1-10
Sci Adv. 2022-10-7
Pain Physician. 2021-3